Spero Therapeutics (SPRO) Free Cash Flow Growth (3y) (2019 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 24.91% |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 20.11% |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 14.71% |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | -10.65% |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 31.42% |
| 10 | Spero Therapeutics | 154.37 Mn | 98.24 Mn | - | 47.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 47.89% |
| Dec 31, 2025 | -29.82% |
| Sep 30, 2025 | 172.37% |
| Jun 30, 2025 | 8.42% |
| Mar 31, 2025 | 47.85% |
| Dec 31, 2024 | 5.02% |
| Sep 30, 2024 | 66.04% |
| Jun 30, 2024 | -4.20% |
| Mar 31, 2024 | 33.58% |
| Dec 31, 2023 | -2.18% |
| Sep 30, 2023 | 40.05% |
| Jun 30, 2023 | 9.34% |
| Mar 31, 2023 | 18.11% |
| Dec 31, 2022 | 65.61% |
| Sep 30, 2022 | 53.75% |
| Jun 30, 2022 | -23.74% |
| Mar 31, 2022 | -36.88% |
| Dec 31, 2021 | -26.34% |
| Sep 30, 2021 | 3.52% |
| Jun 30, 2021 | -24.23% |
| Mar 31, 2021 | -8.97% |
| Dec 31, 2020 | -8.77% |
| Sep 30, 2020 | -26.56% |
| Jun 30, 2020 | -41.05% |
| Mar 31, 2020 | -49.69% |
| Dec 31, 2019 | -22.73% |